Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
HOOKIPA Pharma’s $50 Million Public Offering of Common Stock and Convertible Preferred Stock
Goodwin Procter advised HOOKIPA, and Duane Morris advised the underwriters involved in the offering. HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced its underwritten public offering of 22,900,768...
Sun Pharmaceutical’s $576 Million Acquisition of Concert Pharmaceuticals
Davis Polk advised Sun Pharmaceutical, and Goodwin Procter advised Concert Pharmaceuticals. Sun Pharmaceutical Industries Limited announced its acquisition of Concert Pharmaceuticals Inc., through a tender offer for an...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Omega Therapeutics’ $144.6 Million IPO
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
Minovia Therapeutics’ Collaboration and License Agreement with Astellas Pharma
Goodwin Procter advised Minovia Therapeutics on the deal. Minovia Therapeutics announced its worldwide strategic collaboration and license agreement with Astellas Pharma (TSE: 4503) to research, develop, and...
Rapid Micro Biosystems’ $158.4 Million IPO
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
Cerevel Therapeutics’ $350 Million Public Offering
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
HiFiBiO’s $75 Million Series D Financing Round
Goodwin Procter LLP advised HiFiBiO on the deal. HiFiBiO announced its oversubscribed $75 million Series D financing round. HiFiBiO is a multinational biotechnology company with unique expertise...
COMPASS Pathways’ $144 Million Shares Offering
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...